Instil Bio Inc. reported its financial results for the first quarter ended March 31, 2025. The company experienced a net loss per share of $4.32, an increase from the $3.74 reported for the same period in 2024. However, on a non-GAAP basis, the net loss per share decreased to $1.32 from $2.39 in the prior year. General and administrative expenses fell to $9.1 million from $12.4 million in the previous year, while research and development expenses decreased to $5.4 million from $7.3 million. Restructuring and impairment charges rose significantly to $16.1 million, compared to $4.3 million the previous year. Instil Bio reported $15.4 million in cash and cash equivalents, $1.0 million in restricted cash, $88.3 million in marketable securities, and $7.2 million in long-term investments as of March 31, 2025. The company expects these resources to fund its current operating plan beyond 2026.